STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer

Abstract

We propose that STAT3 inhibition is a viable and potent therapeutic target against Tregs. Our data support the design of clinical trials integrating STAT3 ASO in the standard of care for cancer patients receiving radiation.